Identify Which Patients May Benefit From Evusheld
June 2022
You'll hear buzz about Evusheld (tixagevimab/cilgavimab), the first PRE-exposure prophylaxis med for COVID-19, for patients age 12 and up.
It's a COVID-19 monoclonal antibody ("MAb")...similar to sotrovimab, casirivimab/imdevimab, etc.
Other COVID-19 mabs are IV infusions for TREATMENT...Evusheld is an IM injection for PREVENTION. It has a longer half-life than most mabs...about 90 days after a single dose.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive